Gilead Sciences Archives
COVID treatment studied by VUMC gains FDA approval
Oct. 26, 2020—Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.
New study supports remdesivir as COVID-19 treatment
Jul. 9, 2020—This week researchers at Vanderbilt University Medical Center (VUMC), the University of North Carolina at Chapel Hill and Gilead Sciences reported that remdesivir potently inhibited SARS-CoV-2, the virus which causes COVID-19, in human lung cell cultures and that it improved lung function in mice infected with the virus.
Blueprint for rebuilding the heart
May. 9, 2019—Young-Jae Nam and colleagues are discovering how to express specific factors in connective tissue cells to turn them into heart muscle cells.
Block estrogen to treat lung disease
Aug. 17, 2017—Based on findings from Vanderbilt investigators and others, clinical trials of estrogen inhibition for pulmonary arterial hypertension have recently been approved and funded by the National Institutes of Health.
